Long noncoding ribonucleic acids maternally expressed gene 3 inhibits lung cancer tumor progression through downregulation of MYC

Area of Science:

• Molecular Biology
• Oncology
• Gene Expression

Background:

• Long noncoding RNAs (lncRNAs) are emerging as critical biomarkers and therapeutic targets in human cancers.
• Maternally expressed gene 3 (MEG3) is frequently downregulated in various malignancies, indicating its potential role as a tumor suppressor.

Purpose of the Study:

• To investigate the expression levels of MEG3 in lung cancer (LC) tissues.
• To elucidate the functional role of MEG3 in regulating LC cell proliferation, apoptosis, and migration.
• To explore the relationship between MEG3 and MYC expression in LC.

Main Methods:

• Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to assess MEG3 expression in 40 paired LC tissues.
• Experimental overexpression of MEG3 to evaluate its impact on cell proliferation, apoptosis, and migration using cell counting kit-8, flow cytometry, and Transwell assays.
• qRT-PCR and Western blot analysis to determine MYC messenger RNA and protein levels.

Main Results:

• MEG3 expression was significantly downregulated in LC tissues compared to normal tissues.
• Forced overexpression of MEG3 suppressed cell proliferation and induced apoptosis in LC cells.
• MEG3 overexpression exhibited a moderate inhibitory effect on cell migration in vitro.
• MEG3 was found to inhibit MYC expression at both the transcriptional and translational levels.

Conclusions:

• The findings demonstrate that MEG3 plays a crucial role in regulating lung cancer progression.
• MEG3 functions as a potential tumor suppressor in lung cancer by inhibiting proliferation, migration, and targeting MYC.
• MEG3 represents a promising therapeutic target for lung cancer treatment.